The Board of Directors of Eris Lifesciences is scheduled to meet on November 24, 2025, to consider the issuance of equity shares through a preferential issue. This is in connection with a potential acquisition of the remaining 30% equity stake in Swiss Parenterals Limited. The board will also discuss convening a meeting to seek shareholder approval for the preferential issue.
Board Meeting for Equity Issuance
Eris Lifesciences Limited has announced a board meeting scheduled for November 24, 2025. The primary agenda is to consider the proposal for issuing equity shares through a preferential issue, with consideration other than cash.
Potential Acquisition Stake
This equity issuance is related to a potential acquisition of the remaining 30% stake in Swiss Parenterals Limited. This is subject to necessary approvals.
Shareholder Approval
The Board will also consider the possibility of convening a meeting or using a postal ballot to gain shareholder approval regarding the proposed preferential issue.
Source: BSE